Tyra co-founders Todd Harris (L) and Daniel Bensen

Why do some tar­get­ed can­cer ther­a­pies stop work­ing? For Tyra, that's the $106M ques­tion

Tar­get­ed can­cer ther­a­pies can be quite ef­fec­tive. Un­til, for some pa­tients, the can­cer mu­tates, and the treat­ment stops work­ing.

“It’s not un­like re­sis­tance in an­tibi­otics …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.